organ
pneumonia
op
poorli
understood
complic
hematopoiet
stem
cell
transplant
hsct
identifi
patient
diagnos
op
follow
hsct
describ
clinic
cours
ct
chest
find
remark
multifoc
infiltr
predominantli
consolid
ground
glass
opac
bronchoalveolar
lavag
bal
perform
patient
five
lymphocytosi
lymphocyt
three
eosinophilia
eosinophil
three
neutrophilia
neutrophil
three
normal
cell
count
flow
cytometri
analyz
bal
fluid
patient
initi
treatment
mgkg
prednison
result
improv
symptom
radiograph
find
pulmonari
function
test
major
patient
six
patient
recurr
op
complet
treatment
eleven
patient
evid
extrapulmonari
graftversushost
diseas
prior
diagnosi
op
seven
patient
diagnos
upper
respiratori
tract
infect
uri
within
week
op
diagnosi
patient
respond
well
prednison
signific
improv
pulmonari
function
risk
recurr
high
cessat
steroid
treatment
risk
factor
develop
op
may
includ
prior
uri
advanc
field
allogen
hematopoiet
stem
cell
transplant
hsct
provid
therapi
mani
peopl
suffer
hematolog
malign
opportun
improv
longterm
surviv
graftversushost
diseas
gvhd
multisystem
disord
wherein
donor
immun
cell
recogn
host
tissu
foreign
initi
immun
reaction
gvhd
signific
caus
morbid
mortal
follow
hsct
pulmonari
manifest
gvhd
occur
nearli
patient
gvhd
associ
higher
rate
late
mortal
bronchiol
obliteran
syndrom
bo
defin
new
onset
obstruct
pulmonari
defect
posthsct
patient
without
evid
infect
least
one
extrapulmonari
site
chronic
gvhd
common
pulmonari
manifest
chronic
gvhd
anoth
common
posthsct
pulmonari
complic
organ
pneumonia
op
formerli
refer
bronchiol
obliteran
organ
pneumonia
may
manifest
gvhd
case
op
defin
diffus
interstiti
lung
diseas
typic
afflict
distal
respiratori
bronchiol
alveoli
patchi
distribut
background
lung
architectur
preserv
op
polypoid
intralumin
plug
prolifer
granul
tissu
consist
fibroblast
myofibroblast
loos
connect
matrix
involv
alveoli
alveolar
duct
extend
bronchiol
op
typic
present
nonspecif
symptom
includ
cough
malais
lowgrad
fever
dyspnea
chest
ct
imag
op
featur
diffus
patchi
alveolar
opac
may
consolid
groundglass
typic
case
though
solitari
lesion
describ
focal
op
op
featur
restrict
pattern
pulmonari
function
test
pft
combin
obstruct
restrict
pattern
op
follow
hsct
report
incid
patient
highli
variabl
time
frame
hsct
develop
condit
potenti
transplantrel
risk
factor
develop
op
includ
hla
dispar
peripher
blood
stem
cell
transplant
femaletomal
hsct
cell
deplet
appear
protect
develop
op
bo
sought
review
cohort
patient
diagnos
posthsct
op
particular
interest
focus
bronchoscop
find
diagnost
workup
potenti
risk
factor
develop
op
treatment
outcom
patient
identifi
univers
kansa
medic
center
adult
hematopoiet
stem
cell
transplant
clinic
patient
histori
allogen
hsct
develop
op
follow
hsct
diagnosi
op
base
clinic
featur
typic
radiograph
find
exclus
infecti
etiolog
altern
diagnos
could
assess
bronchoscopi
serolog
test
addit
patient
persist
symptom
radiograph
chang
complet
appropri
cours
empir
broadspectrum
antimicrobi
diagnosi
op
made
diagnost
test
perform
exclud
infect
includ
standard
bacteri
fungal
cultur
serum
serum
galactomannan
antigen
serum
betadglucan
assay
bal
fluid
standard
bacteri
fungal
acidfast
bacteri
cultur
galactomannan
antigen
pneumocysti
carinii
pcr
herp
simplex
viru
pcr
cytomegaloviru
pcr
grocott
stain
perform
nxtag
respiratori
pathogen
panel
pcr
also
perform
bal
specimen
assess
influenza
influenza
b
respiratori
syncyti
viru
b
rhinoviru
parainfluenza
viru
human
metapneumoviru
adenoviru
coronaviru
bordetella
pertussi
chlamydophila
pneuomonia
mycoplasma
pneumonia
typic
symptom
time
diagnosi
includ
new
onset
respiratori
symptom
posthsct
includ
cough
dyspnea
pleurisi
patient
pulmonari
infiltr
ct
imag
chest
typic
featur
op
includ
lung
consolid
groundglass
opac
patient
diagnosi
confirm
exclus
infecti
caus
includ
perform
bronchoscopi
bronchoalveolar
lavag
bal
indic
lung
biopsi
either
bronchoscop
via
transbronchi
lung
biopsi
open
surgic
lung
biopsi
typic
perform
patient
popul
due
risk
complic
follow
diagnosi
op
initi
followup
ct
scan
rang
day
patient
typic
follow
everi
day
pulmonologist
addit
imag
clinic
indic
data
collect
includ
background
inform
hsct
detail
site
gvhd
occurr
ct
find
symptom
bal
find
treatment
pft
result
outcom
collect
includ
time
resolut
symptom
time
resolut
infiltr
total
durat
prednison
treatment
complic
surviv
patient
identifi
juli
januari
censorship
data
occur
june
studi
perform
approv
univers
kansa
medic
center
institut
review
board
p
valu
determin
use
anova
analysi
identifi
patient
diagnos
op
follow
hsct
mean
age
year
rang
year
male
period
time
patient
underw
allogen
hsct
institut
give
preval
patient
variou
underli
hematolog
malign
includ
eight
aml
ten
patient
underw
hsct
unrel
donor
three
patient
histori
underli
lung
diseas
four
patient
histori
tobacco
use
full
background
characterist
patient
describ
tabl
mean
onset
symptom
day
transplant
patient
present
cough
dyspnea
exert
symptom
also
includ
fever
pleurit
chest
pain
clinic
featur
prior
diagnosi
op
includ
histori
extrapulmonari
gvhd
patient
oppos
incid
allogen
hsct
patient
seven
patient
diagnos
upper
respiratori
tract
infect
uri
within
week
diagnos
op
twelv
patient
patient
op
receiv
total
bodi
irradi
tbi
condit
regimen
time
frame
patient
underw
allogen
hsct
institut
receiv
tbi
full
detail
symptom
radiograph
characterist
bronchoscop
find
shown
tabl
ct
chest
find
time
diagnosi
remark
multifoc
infiltr
patient
infiltr
describ
ground
glass
opac
six
patient
consolid
two
patient
nodular
four
patient
mix
pattern
three
patient
time
present
op
patient
averag
reduct
fvc
p
valu
p
valu
respect
compar
pretranspl
pft
fig
addit
averag
reduct
total
lung
capac
tlc
residu
volum
rv
diffus
capac
dlco
respect
bronchoalveolar
lavag
bal
cell
differenti
perform
patient
five
patient
featur
lymphocytosi
lymphocyt
three
eosinophilia
eosinophil
three
neutrophilia
neutrophil
three
normal
cell
count
flow
cytometri
analyz
bal
fluid
patient
firstlin
treatment
detail
op
shown
tabl
averag
initi
dose
prednison
mgkgday
rang
mgkgday
steroidspar
therapi
introduc
firstlin
treatment
includ
rituximab
ruxolitinib
rextracorpor
photopheresi
ecp
prescrib
three
patient
treatment
outcom
shown
tabl
patient
symptom
improv
treatment
averag
day
treatment
initi
rang
day
followup
ct
scan
demonstr
averag
time
resolut
infiltr
day
rang
day
one
patient
resolut
infiltr
treatment
averag
patient
receiv
steroid
treatment
day
day
complic
steroid
treatment
includ
develop
insomnia
diabet
steroidinduc
myopathi
pft
perform
time
steroid
complet
show
increas
fvc
respect
compar
pft
complet
time
op
diagnosi
fig
addit
period
time
tlc
rv
dlco
increas
chang
decreas
follow
treatment
steroid
respect
pft
remain
stabl
major
patient
term
outcom
eight
patient
recurr
op
patient
recurr
three
treat
prednison
monotherapi
one
resolut
three
patient
treat
combin
prednison
ruxolitinib
two
resolut
one
patient
treat
combin
prednison
rituximab
resolut
final
patient
treat
ecp
rituximab
resolut
though
improv
pft
imag
five
patient
ultim
die
one
patient
death
attribut
respiratori
failur
secondari
op
review
cohort
patient
diagnos
op
follow
hsct
found
variabl
underli
hematolog
process
condit
regimen
preexist
pulmonari
diseas
patient
present
similar
symptom
seven
patient
document
viral
uri
within
week
op
diagnosi
variabl
cell
count
seen
bal
seen
patient
observ
respons
system
corticosteroid
major
patient
improv
pft
though
patient
requir
secondlin
therapi
bronchoscopi
bal
valuabl
tool
evalu
pulmonari
infiltr
unknown
etiolog
immunosuppress
patient
utmost
import
exclud
infecti
etiolog
patient
popul
earli
bronchoscopi
provid
higher
yield
possibl
improv
surviv
found
wide
variabl
alveolar
cell
count
identifi
bal
reduc
ratio
encount
known
find
nonhsctrel
op
transbronchi
lung
biopsi
gener
avoid
patient
popul
due
low
associ
yield
risk
complic
wherea
open
lung
biopsi
typic
recommend
confirm
diagnosi
op
nonhsct
popul
feel
exclud
infecti
etiolog
bal
narrow
differenti
diagnosi
substanti
expedit
treatment
avoid
complic
openlung
biopsi
declin
use
hsct
recipi
popul
treat
corticosteroid
firstlin
therapi
op
line
current
recommend
side
effect
profil
corticosteroid
problemat
effect
manag
op
hsct
recipi
receiv
hsct
accept
standard
care
major
patient
manag
corticosteroid
alon
initi
treatment
though
eight
patient
recurr
op
beg
question
long
optim
durat
steroid
therapi
entiti
benefici
extend
one
year
patient
without
histori
hsct
common
agent
employ
persist
recurr
op
includ
cyclophosphamid
macrolid
rituximab
popul
hsct
recipi
agent
employ
recurr
diseas
includ
ecp
rituximab
ruxolitinib
either
alon
combin
mix
result
among
group
agent
use
success
treatment
steroidresist
steroidrefractori
gvhd
includ
patient
bo
pulmonari
manifest
gvhd
determin
optim
agent
use
recurr
steroidresist
op
due
gvhd
requir
ongo
clinic
trial
care
attent
outcom
etiolog
posthsct
op
unclear
time
tempt
assum
manifest
pulmonari
gvhd
unclear
cohort
patient
extrapulmonari
manifest
gvhd
previou
studi
shown
potenti
associ
use
irradi
condit
regimen
util
patient
anoth
potenti
caus
op
patient
includ
previou
viral
infect
document
seven
patient
dysregul
airway
inflamm
may
mechan
explain
progress
uri
op
hsct
recipi
studi
mani
limit
first
retrospect
studi
singlecent
rare
lung
diseas
follow
hsct
addit
patient
treat
nonuniform
manner
use
steroidspar
agent
vari
among
particip
studi
variat
treatment
choic
larg
driven
inequ
drug
avail
variou
patient
often
driven
manag
care
decis
unfortun
quit
heterogen
patient
popul
mani
limit
relat
variabl
present
respons
treatment
inflammatori
lung
diseas
popul
quit
heterogen
common
link
popul
exclus
altern
diagnos
gener
steroidrespons
diseas
summari
op
condit
may
occur
follow
hsct
diagnos
base
characterist
radiograph
pattern
exclus
infecti
etiolog
typic
bal
patient
may
declin
lung
function
onset
op
though
typic
revers
treatment
op
corticosteroid
remain
standard
firstlin
therapi
though
use
secondlin
agent
often
requir
steroidresist
recurr
diseas
local
institut
review
board
gave
approv
studi
